Company Overview and News

0
BRP annonce l’élection de ses administrateurs

2018-05-31 globenewswire
VALCOURT, Québec, 31 mai 2018 (GLOBE NEWSWIRE) -- BRP inc. (TSX:DOO) a tenu plus tôt aujourd’hui son assemblée annuelle des actionnaires à Valcourt, au Québec. Tous les candidats aux postes d’administrateurs figurant dans la circulaire de sollicitation de procurations de la direction de la Société datée du 20 avril 2018 ont été élus par une majorité des votes des actionnaires présents ou représentés par procuration à l’assemblée.
DOO

0
BRP Announces Election of Directors

2018-05-31 globenewswire
VALCOURT, Québec, May 31, 2018 (GLOBE NEWSWIRE) -- BRP Inc. (TSX:DOO) held earlier today its annual meeting of shareholders in Valcourt, Québec. All of the nominees for directors listed in the Company's management proxy circular dated April 20, 2018 were elected by a majority of the votes cast by shareholders present or represented by proxy at the meeting. The voting result for each nominee is as follows:
DOO

0
Avis aux médias : BRP Inc. publiera ses résultats du 1er trimestre de l’AF2019 et tiendra son assemblée annuelle des actionnaires

2018-05-17 globenewswire
VALCOURT, Québec, 17 mai 2018 (GLOBE NEWSWIRE) -- BRP Inc. (TSX:DOO) tiendra un appel conférence sur les résultats de son premier trimestre de l’année financière 2019 le jeudi 31 mai 2018 et poursuivra avec son assemblée annuelle des actionnaires.
DOO

0
Media Advisory: BRP Will Present Its First Quarter FY2019 Results And Hold Its Annual Meeting Of Shareholders

2018-05-17 globenewswire
VALCOURT, Quebec, May 17, 2018 (GLOBE NEWSWIRE) -- BRP Inc. (TSX:DOO) will hold its first quarter FY2019 financial results conference call on Thursday, May 31, 2018, followed by its annual meeting of shareholders.
DOO

0
BRP Establishes Automatic Share Purchase Plan

2018-04-20 globenewswire
VALCOURT, Quebec, April 20, 2018 (GLOBE NEWSWIRE) -- BRP Inc. (TSX:DOO) announced today that, in connection with its previously announced normal course issuer bid to purchase for cancellation up to 3,625,271 subordinate voting shares of BRP (the “NCIB”), it entered into an automatic share purchase plan (the “APP”) with a designated broker. This is intended to allow for the purchase of subordinate voting shares under the NCIB at times when BRP would ordinarily not be permitted to purchase shares due to regulatory restrictions or self-imposed blackout periods.
DOO

0
BRP établit un programme de rachat d’actions automatique

2018-04-20 globenewswire
VALCOURT, Québec, 20 avr. 2018 (GLOBE NEWSWIRE) -- BRP Inc. (TSX:DOO) a annoncé aujourd’hui qu’elle a établi, dans le cadre de son offre publique de rachat dans le cours normal des activités déjà annoncée visant le rachat, aux fins d’annulation, d’au plus 3,625,271 actions à droit de vote subalterne de BRP (l’« offre publique de rachat »), un programme de rachat d’actions automatique (le « PRA ») avec un courtier désigné afin de pouvoir racheter des actions à droit de vote subalterne aux termes de l’offre publique de rachat à des moments où elle ne pourrait pas normalement en racheter en raison de restrictions de nature réglementaire ou de périodes d’interdiction d’opérations auto-imposées.
DOO

0
BRP publie les résultats de son quatrième trimestre et son année financière 2018 record

2018-03-21 globenewswire
VALCOURT, Québec, 21 mars 2018 (GLOBE NEWSWIRE) -- BRP Inc. (TSX:DOO) a publié aujourd’hui ses résultats financiers pour le trimestre et l’année terminés le 31 janvier 2018. Notez qu’à moins d’indication contraire, toutes les données sont en dollars canadiens. Les résultats financiers complets sont disponibles au www.sedar.com, ainsi que sur la section Rapports trimestriels du site web de BRP.
DOO

0
BRP Announces the Renewal of Its Normal Course Issuer Bid

2018-03-21 globenewswire
VALCOURT, Québec, March 21, 2018 (GLOBE NEWSWIRE) -- BRP Inc. (TSX:DOO) announced today that its Board of Directors has authorized the renewal of its normal course issuer bid to purchase for cancellation up to 3,625,271 subordinate voting shares over the twelve-month period commencing on April 2, 2018 and ending no later than April 1, 2019, representing approximately 10% of the public float of 36,252,716 subordinate voting shares as at March 19, 2018.
DOO

0
BRP Reports Fourth-Quarter and Record Fiscal Year 2018 Results

2018-03-21 globenewswire
VALCOURT, Québec, March 21, 2018 (GLOBE NEWSWIRE) -- BRP Inc. (TSX:DOO) today reported its financial results for the three- and twelve-month periods ended January 31, 2018. All financial information is in Canadian dollars unless otherwise noted. The complete financial results are available at www.sedar.com, as well as in the Quarterly Reports section of BRP’s website.
DOO

0
BRP annonce le renouvellement de son offre publique de rachat dans le cours normal des activités

2018-03-21 globenewswire
VALCOURT, Québec, 21 mars 2018 (GLOBE NEWSWIRE) -- BRP Inc. (TSX:DOO) a annoncé aujourd’hui que son conseil d’administration a autorisé le renouvellement de son offre publique de rachat dans le cours normal des activités afin de racheter, aux fins d’annulation, au plus 3 625 271 actions à droit de vote subalterne au cours de la période de douze mois débutant le 2 avril 2018 et prenant fin au plus tard le 1er avril 2019, soit environ 10 % du flottant des 36 252 716 actions à droit de vote subalterne au 19 mars 2018.
DOO

0
REMINDER: BRP to Present Its Fourth-Quarter and Fiscal Year 2018 Results

2018-03-16 globenewswire
VALCOURT, Québec, March 16, 2018 (GLOBE NEWSWIRE) -- BRP Inc. (TSX:DOO) will hold its fourth-quarter and fiscal year 2018 financial results conference call on Wednesday, March 21, 2018 at 9 a.m. (ET). José Boisjoli, President and Chief Executive Officer, and Sébastien Martel, Chief Financial Officer, will discuss the results and address questions from analysts.
DOO

0
RAPPEL : BRP publiera les résultats du quatrième trimestre et de l'exercice financier 2018

2018-03-16 globenewswire
VALCOURT, Québec, 16 mars 2018 (GLOBE NEWSWIRE) -- BRP Inc. (TSX:DOO) tiendra un appel conférence sur les résultats de son quatrième trimestre et de l'exercice financier 2018 le mercredi 21 mars 2018 à 9 h (HE). MM. José Boisjoli, président et chef de la direction, et Sébastien Martel, chef de la direction financière, présenteront les résultats et répondront aux questions des analystes.
DOO

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

9h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to TSX:DOO / Brp Inc on message board site Silicon Investor.

Manmade Global Warming, A hoax? A Scam? or a Doomsday Cult? Hadoop software companies
Doom and Gloom Scenarios Hidden door
Canoes, Hiking, the Great Outdoors IBIS, DXNGY, the u0026quot;Millionaire Next Dooru0026quot;, Articles
OMDO: Omni Doors, Inc. MCTL - Dooby Dooby Dooo
VOODOOu0027S FLAMING CHAINSAWS AND OTHER DANGEROUS STUFF Bill Wexleru0027s Profits of DOOM